Brimonidine Tartrate 0.15%, Dorzolamide Hydrochloride 2%, and Brinzolamide 1% Compared as Adjunctive Therapy to Prostaglandin Analogs

Ophthalmology

Volumn 116, Issue 9, 2009, Pages 1719-1724

  Bournias, Thomas E ^a   Lai, Jerry ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; LATANOPROST; PROSTAGLANDIN DERIVATIVE; TRAVOPROST;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EYE DISCOMFORT; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; AMIDES; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; QUINOXALINES; SINGLE-BLIND METHOD; SULFONAMIDES; THIAZINES; THIOPHENES; TONOMETRY, OCULAR; TREATMENT OUTCOME;

EID: 69249214004     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.03.050     Document Type: Article

References (25)

1. van der Valk R., Webers C.A., Schouten J.S., et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 112 (2005) 1177-1185
2. McKee H.D., Gupta M.S., Ahad M.A., et al. First-choice treatment preferences for primary open-angle glaucoma in the United Kingdom [letter]. Eye 19 (2005) 923-924
3. Kass M.A., Heuer D.K., Higginbotham E.J., et al., Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120 (2002) 701-713
4. Lichter P.R., Musch D.C., Gillespie B.W., et al., CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 108 (2001) 1943-1953
5. Covert D., and Robin A.L. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Curr Med Res Opin 22 (2006) 971-976
6. Higginbotham E.J., Feldman R., Stiles M., Dubiner H., and Fixed Combination Investigative Group. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol 120 (2002) 915-922
7. Toris C.B., Alm A., and Camras C.B. Latanoprost and cholinergic agonists in combination. Surv Ophthalmol 47 suppl (2002) S141-S147
8. Konstas A.G., Karabatsas C.H., Lallos N., et al. 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. Ophthalmology 112 (2005) 603-608
9. Mundorf T., Noecker R.J., and Earl M. Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension. Adv Ther 24 (2007) 302-309
10. Feldman R.M., Tanna A.P., Gross R.L., et al. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%. Ophthalmology 114 (2007) 1248-1254
11. Nakamoto K., and Yasuda N. Effect of concomitant use of latanoprost and brinzolamide on 24-hour variation of IOP in normal-tension glaucoma. J Glaucoma 16 (2007) 352-357
12. Shoji N., Ogata H., Suyama H., et al. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study. Curr Med Res Opin 21 (2005) 503-508
13. Tamer C., and Oksuz H. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost. Ophthalmic Res 39 (2007) 24-31
14. Maruyama K., and Shirato S. Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial. J Glaucoma 15 (2006) 341-345
15. Lenth R.V. Java Applets for Power and Sample Size [Computer software] (2006). http://www.stat.uiowa.edu/∼rlenth/Power Accessed December 23, 2008
16. Leske M.C., Heijl A., Hussein M., et al., Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol 121 (2003) 48-56
17. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130 (2000) 429-440
18. Olthoff C.M., Schouten J.S., van de Borne B.W., and Webers C.A. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review. Ophthalmology 112 (2005) 953-961
19. Neelakantan A., Vaishnav H.D., Iyer S.A., and Sherwood M.B. Is addition of a third or fourth antiglaucoma medication effective?. J Glaucoma 13 (2004) 130-136
20. Stewart W.C., Sharpe E.D., Harbin Jr. T.S., et al. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure. Am J Ophthalmol 129 (2000) 723-727
21. Sharpe E.D., Day D.G., Beischel C.J., et al. Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension. Br J Ophthalmol 88 (2004) 953-956
22. Silver L.H., and Brinzolamide Primary Therapy Study Group. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 126 (1998) 400-408
23. Day D.G., and Hollander D.A. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension. Curr Med Res Opin 24 (2008) 1435-1442
24. Katz L.J. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 11 (2002) 119-126
25. Michaud J.E., Friren B., and International Brinzolamide Adjunctive Study Group. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol 132 (2001) 235-243